SI1796668T1 - Vodni farmacevtski pripravek, ki obsega roflumilast - Google Patents
Vodni farmacevtski pripravek, ki obsega roflumilastInfo
- Publication number
- SI1796668T1 SI1796668T1 SI200530511T SI200530511T SI1796668T1 SI 1796668 T1 SI1796668 T1 SI 1796668T1 SI 200530511 T SI200530511 T SI 200530511T SI 200530511 T SI200530511 T SI 200530511T SI 1796668 T1 SI1796668 T1 SI 1796668T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical preparation
- roflumilast
- aqueous pharmaceutical
- administration
- aqueous
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title 1
- 229960002586 roflumilast Drugs 0.000 title 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004046235A DE102004046235A1 (de) | 2004-09-22 | 2004-09-22 | Arzneimittelzubereitung |
| EP05794694A EP1796668B1 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1796668T1 true SI1796668T1 (sl) | 2009-02-28 |
Family
ID=35447576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200530511T SI1796668T1 (sl) | 2004-09-22 | 2005-09-21 | Vodni farmacevtski pripravek, ki obsega roflumilast |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9205044B2 (sl) |
| EP (1) | EP1796668B1 (sl) |
| JP (1) | JP5044404B2 (sl) |
| AT (1) | ATE408405T1 (sl) |
| AU (1) | AU2005286476B2 (sl) |
| CA (1) | CA2580397C (sl) |
| CY (1) | CY1109407T1 (sl) |
| DE (2) | DE102004046235A1 (sl) |
| DK (1) | DK1796668T3 (sl) |
| ES (1) | ES2314718T3 (sl) |
| HR (1) | HRP20080640T3 (sl) |
| ME (1) | ME01050B (sl) |
| PL (1) | PL1796668T3 (sl) |
| PT (1) | PT1796668E (sl) |
| RS (1) | RS50641B (sl) |
| SI (1) | SI1796668T1 (sl) |
| WO (1) | WO2006032675A1 (sl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US8795634B2 (en) * | 2008-09-12 | 2014-08-05 | Critical Pharmaceuticals Limited | Absorption of therapeutic agents across mucosal membranes or the skin |
| WO2010132507A2 (en) | 2009-05-11 | 2010-11-18 | Cytotech Labs, Llc | Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
| GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| NZ720022A (en) | 2010-03-12 | 2018-07-27 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| EP3320902B1 (en) * | 2011-03-07 | 2021-02-17 | Amgen (Europe) GmbH | Methods for treating diseases using isoindoline compounds |
| ES2762451T3 (es) | 2011-04-04 | 2020-05-25 | Berg Llc | Tratamiento de tumores del sistema nervioso central con coenzima Q10 |
| CN102793684B (zh) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | 罗氟司特液体制剂及其制备方法 |
| MY183615A (en) | 2011-06-17 | 2021-03-03 | Berg Llc | Inhalable pharmaceutical compositions |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| EP2983654B1 (en) | 2013-04-08 | 2025-11-12 | BPGbio, Inc. | Treatment of cancer using coenzyme q10 combination therapies |
| TW201540301A (zh) | 2013-08-16 | 2015-11-01 | Takeda Gmbh | 以ｐｄｅ４抑制劑治療認知損傷 |
| AU2014315186B2 (en) | 2013-09-04 | 2020-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
| CN105287366B (zh) * | 2014-06-18 | 2018-02-16 | 张蕊 | 一种维生素k1注射液及其制备方法 |
| CN106573889B (zh) | 2014-10-24 | 2019-01-01 | 久光制药株式会社 | 前药 |
| WO2017007957A1 (en) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Reduced sodium poloxamer-188 formulations and methods for use |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
| KR102117525B1 (ko) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물 |
| CA3166300A1 (en) | 2020-01-31 | 2021-08-05 | David W. Osborne | Topical roflumilast formulation having improved delivery and plasma half-life |
| CN115666652A (zh) * | 2020-02-03 | 2023-01-31 | 千寿制药株式会社 | 聚醚系化合物的用途 |
| MX2023006602A (es) | 2020-12-04 | 2023-08-07 | Arcutis Biotherapeutics Inc | Formulación tópica de roflumilast que tiene propiedades antimicoticas. |
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| IL304924A (en) | 2021-02-10 | 2023-10-01 | Iolyx Therapeutics Inc | Methods for ophthalmic delivery of roflumilast |
| MX2024003580A (es) | 2021-09-22 | 2024-04-05 | Iolyx Therapeutics Inc | Metodos de tratamiento de enfermedades inflamatorias oculares. |
| IL313866A (en) | 2021-12-28 | 2024-08-01 | Arcutis Biotherapeutics Inc | Topical roflomilest spray foams |
| JP2025530005A (ja) | 2022-09-15 | 2025-09-09 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2165192C (en) | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| AU755445B2 (en) * | 1998-05-07 | 2002-12-12 | Corixa Corporation | Adjuvant composition and methods for its use |
| EP1161239B1 (en) | 1999-03-10 | 2004-10-20 | ALTANA Pharma AG | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ATE485821T1 (de) * | 2002-05-28 | 2010-11-15 | Nycomed Gmbh | Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen |
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| PL213925B1 (pl) * | 2002-07-19 | 2013-05-31 | Abbott Biotech Ltd | Przeciwcialo anty-TNFα lub jego czesc wiazaca antygen, ich zastosowanie oraz zestaw |
-
2004
- 2004-09-22 DE DE102004046235A patent/DE102004046235A1/de not_active Withdrawn
-
2005
- 2005-09-21 WO PCT/EP2005/054723 patent/WO2006032675A1/en not_active Ceased
- 2005-09-21 AT AT05794694T patent/ATE408405T1/de active
- 2005-09-21 DK DK05794694T patent/DK1796668T3/da active
- 2005-09-21 ME MEP-2008-797A patent/ME01050B/me unknown
- 2005-09-21 EP EP05794694A patent/EP1796668B1/en not_active Expired - Lifetime
- 2005-09-21 ES ES05794694T patent/ES2314718T3/es not_active Expired - Lifetime
- 2005-09-21 CA CA2580397A patent/CA2580397C/en not_active Expired - Fee Related
- 2005-09-21 AU AU2005286476A patent/AU2005286476B2/en not_active Ceased
- 2005-09-21 RS RSP-2008/0591A patent/RS50641B/sr unknown
- 2005-09-21 PL PL05794694T patent/PL1796668T3/pl unknown
- 2005-09-21 SI SI200530511T patent/SI1796668T1/sl unknown
- 2005-09-21 HR HR20080640T patent/HRP20080640T3/xx unknown
- 2005-09-21 US US11/662,887 patent/US9205044B2/en not_active Expired - Fee Related
- 2005-09-21 DE DE602005009848T patent/DE602005009848D1/de not_active Expired - Lifetime
- 2005-09-21 JP JP2007531767A patent/JP5044404B2/ja not_active Expired - Fee Related
- 2005-09-21 PT PT05794694T patent/PT1796668E/pt unknown
-
2008
- 2008-12-10 CY CY20081101429T patent/CY1109407T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE102004046235A1 (de) | 2006-03-30 |
| DE602005009848D1 (de) | 2008-10-30 |
| EP1796668B1 (en) | 2008-09-17 |
| JP2008513416A (ja) | 2008-05-01 |
| US20070259009A1 (en) | 2007-11-08 |
| PT1796668E (pt) | 2008-12-22 |
| AU2005286476A1 (en) | 2006-03-30 |
| US9205044B2 (en) | 2015-12-08 |
| HRP20080640T3 (en) | 2009-01-31 |
| CA2580397C (en) | 2013-07-30 |
| RS50641B (sr) | 2010-06-30 |
| DK1796668T3 (da) | 2009-02-02 |
| ME01050B (me) | 2012-10-20 |
| EP1796668A1 (en) | 2007-06-20 |
| JP5044404B2 (ja) | 2012-10-10 |
| CA2580397A1 (en) | 2006-03-30 |
| CY1109407T1 (el) | 2014-07-02 |
| ATE408405T1 (de) | 2008-10-15 |
| AU2005286476B2 (en) | 2011-11-10 |
| WO2006032675A1 (en) | 2006-03-30 |
| ES2314718T3 (es) | 2009-03-16 |
| PL1796668T3 (pl) | 2009-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1796668E (pt) | Preparação farmacêutica aquosa compreendendo roflumilast | |
| GEP20105083B (en) | A solid pharmaceutical dosage formulation | |
| AU2002350719A1 (en) | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base | |
| IL163642A0 (en) | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative | |
| WO2006007448A3 (en) | Pharmaceutical co-crystal compositions and related methods of use | |
| PT1687305E (pt) | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase | |
| BRPI0507654A (pt) | composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv | |
| EP2258350A3 (en) | Taste masked dosage form containing roflumilast | |
| WO2005089718A3 (en) | Pharmaceutical compositions | |
| DK1678162T3 (da) | P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne | |
| WO2004071374A3 (en) | Once a day orally administered pharmaceutical compositions | |
| IL179719A0 (en) | Process for preparation of amorphous form of drug | |
| MXPA05011248A (es) | Derivados de wortmanina solubles en agua. | |
| WO2006044805A3 (en) | Less abusable pharmaceutical preparations | |
| WO2008070495A3 (en) | Short term slow release drug delivery system | |
| TW200744583A (en) | Statin stabilizing dosage formulations | |
| GEP20115222B (en) | New pharmaceutical compounds | |
| UA91904C2 (en) | Salt of cd 80 antagonist | |
| AU2003260239A1 (en) | Solid dosage forms for rapid dissolution of poorly soluble drugs | |
| WO2008009802A3 (fr) | Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies | |
| WO2005105081A3 (en) | Therapeutic formulations of desoxyepothilones | |
| WO2005023223A3 (de) | Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe | |
| WO2005097192A3 (en) | Active substance combination of a carbinol compound and an opioid | |
| WO2008003013A3 (en) | Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic | |
| TW200621304A (en) | Pharmaceutical composition |